Value of 11C-methionine PET in Imaging Brain Tumours and Metastases

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2012 Dec 13

PMID 23232505

Citations 119

Authors

Andor W J M Glaudemans

Roelien H Enting

Mart A A M Heesters

Rudi A J O Dierckx

Ronald W J van Rheenen

Annemiek M E Walenkamp

Riemer H J A Slart

Affiliations

Soon will be listed here.

Abstract

(11)C-methionine (MET) is the most popular amino acid tracer used in PET imaging of brain tumours. Because of its characteristics, MET PET provides a high detection rate of brain tumours and good lesion delineation. This review focuses on the role of MET PET in imaging cerebral gliomas. The Introduction provides a clinical overview of what is important in primary brain tumours, recurrent brain tumours and brain metastases. The indications for radiotherapy and the results and problems arising after chemoradiotherapy in relation to imaging (pseudoprogression or radionecrosis) are discussed. The working mechanism, scan interpretation and quantification possibilities of MET PET are then explained. A literature overview is given of the role of MET PET in primary gliomas (diagnostic accuracy, grading, prognosis, assessment of tumour extent, biopsy and radiotherapy planning), in brain metastases, and in the differentiation between tumour recurrence and radiation necrosis. Finally, MET PET is compared to other nuclear imaging possibilities in brain tumour imaging.

Citing Articles

The Role of 11C-Methionine PET Imaging for the Evaluation of Lymphomas: A Systematic Review.

Dondi F, Gazzilli M, Vigano G, Pisani A, Ferrari C, Rubini G Hematol Rep. 2024; 16(4):752-768.

PMID: 39728002 PMC: 11675220. DOI: 10.3390/hematolrep16040072.

Enhancing Glioblastoma Resection with NIR Fluorescence Imaging: A Systematic Review.

Mansour H, Shah S, Aguilar T, Abdul-Muqsith M, Gonzales-Portillo G, Mehta A Cancers (Basel). 2024; 16(23).

PMID: 39682171 PMC: 11639985. DOI: 10.3390/cancers16233984.

Value of 11C-Methionine PET Imaging in High-Grade Gliomas: A Narrative Review.

Debreczeni-Mate Z, Freihat O, Toro I, Simon M, Kovacs A, Sipos D Cancers (Basel). 2024; 16(18).

PMID: 39335171 PMC: 11429583. DOI: 10.3390/cancers16183200.

Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma.

Kim D, Lee S, Hwang H, Kim S, Yun M Nucl Med Mol Imaging. 2024; 58(4):237-245.

PMID: 38932755 PMC: 11196511. DOI: 10.1007/s13139-024-00847-4.

C-Methionine uptake in meningiomas after stereotactic radiotherapy.

Jeltema H, van Dijken B, Tamasi K, Drost G, Heesters M, van der Hoorn A Ann Nucl Med. 2024; 38(8):596-606.

PMID: 38720053 PMC: 11282149. DOI: 10.1007/s12149-024-01932-6.

References

Douw L, Klein M, Fagel S, van den Heuvel J, Taphoorn M, Aaronson N . Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009; 8(9):810-8. DOI: 10.1016/S1474-4422(09)70204-2. View

Moulin-Romsee G, DHondt E, de Groot T, Goffin J, Sciot R, Mortelmans L . Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine?. Eur J Nucl Med Mol Imaging. 2007; 34(12):2082-7. DOI: 10.1007/s00259-007-0557-4. View

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent M . Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9(5):453-61. DOI: 10.1016/S1470-2045(08)70125-6. View

Giglio P, Gilbert M . Cerebral radiation necrosis. Neurologist. 2003; 9(4):180-8. DOI: 10.1097/01.nrl.0000080951.78533.c4. View

Viader F, Derlon J, Shishido F, Hubert P, Houtteville J, Courtheoux P . Recurrent oligodendroglioma diagnosed with 11C-L-methionine and PET: a case report. Eur Neurol. 1993; 33(3):248-51. DOI: 10.1159/000116947. View

Lee I, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J . Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2008; 73(2):479-85. PMC: 2652133. DOI: 10.1016/j.ijrobp.2008.04.050. View

Chang E, Wefel J, Hess K, Allen P, Lang F, Kornguth D . Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10(11):1037-44. DOI: 10.1016/S1470-2045(09)70263-3. View

Tsao M, Lloyd N, Wong R, Chow E, Rakovitch E, Laperriere N . Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev. 2006; (3):CD003869. DOI: 10.1002/14651858.CD003869.pub2. View

Goldman S, Levivier M, Pirotte B, BRUCHER J, Wikler D, Damhaut P . Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med. 1997; 38(9):1459-62. View

10.

Sadeghi N, Salmon I, Decaestecker C, Levivier M, Metens T, Wikler D . Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol. 2007; 28(3):455-61. PMC: 7977817. View

11.

Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D . Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006; 24(18):2707-14. DOI: 10.1200/JCO.2005.04.3414. View

12.

Lagerwaard F, Levendag P, Nowak P, Eijkenboom W, Hanssens P, Schmitz P . Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999; 43(4):795-803. DOI: 10.1016/s0360-3016(98)00442-8. View

13.

Pouratian N, Schiff D . Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010; 10(3):224-31. PMC: 2857752. DOI: 10.1007/s11910-010-0105-7. View

14.

Posner J . Management of brain metastases. Rev Neurol (Paris). 1992; 148(6-7):477-87. View

15.

Kameyama M, Shirane R, Itoh J, Sato K, Katakura R, Yoshimoto T . The accumulation of 11C-methionine in cerebral glioma patients studied with PET. Acta Neurochir (Wien). 1990; 104(1-2):8-12. DOI: 10.1007/BF01842885. View

16.

SHELINE G . Radiotherapy for high grade gliomas. Int J Radiat Oncol Biol Phys. 1990; 18(4):793-803. DOI: 10.1016/0360-3016(90)90399-5. View

17.

Cairncross G, Jenkins R . Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J. 2008; 14(6):352-7. DOI: 10.1097/PPO.0b013e31818d8178. View

18.

Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins V, Bergstrom M . Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol. 1989; 30(3):225-32. View

19.

Massager N, David P, Goldman S, Pirotte B, Wikler D, Salmon I . Combined magnetic resonance imaging- and positron emission tomography-guided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients. J Neurosurg. 2000; 93(6):951-7. DOI: 10.3171/jns.2000.93.6.0951. View

20.

Chung J, Kim Y, Kim S, Lee Y, Paek S, Yeo J . Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002; 29(2):176-82. DOI: 10.1007/s00259-001-0690-4. View